Dashboard
Manage Tickers

ACRS Aclaris Therapeutics, Inc.


$ 2.54 $ 0.16 (6.69 %)    

Friday, 21-Nov-2025 14:46:18 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 594.66 $ 7.33 (1.25 %)
DIA $ 464.71 $ 5.24 (1.14 %)
SPY $ 662.56 $ 7.55 (1.15 %)
TLT $ 89.46 $ -0.20 (-0.22 %)
GLD $ 376.00 $ 2.00 (0.53 %)
$ na
$ 2.42
$ 2.53 x 471
$ 2.54 x 349
$ 2.36 - $ 2.56
$ 1.05 - $ 4.55
860,218
na
261.11M
$ 1.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

aclaris-therapeutics-q3-eps-012-beats-014-estimate-sales-3299m-beat-1405m-estimate
Aclaris Therapeutics Q3 EPS $(0.12) Beats ...
11/06/2025 12:24:58

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of ...

hc-wainwright--co-reiterates-buy-on-aclaris-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Acla...
10/20/2025 11:39:29

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $1...

aclaris-therapeutics-to-host-2025-rd-day-in-midtown-new-york-on-october-14-to-discuss-its-progress-in-addressing-therapeutic-gaps-in-immuno-inflammatory-markets
Aclaris Therapeutics To Host 2025 R&D Day ...
09/30/2025 11:14:19

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candid...

aclaris-therapeutics-ati-2138-phase-2a-trial-results-to-be-presented-at-2025-eadv-congress-in-paris-for-moderate-to-severe-atopic-dermatitis
Aclaris Therapeutics' ATI-2138 Phase 2a Tr...
09/09/2025 11:20:22

- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis-WAYNE, Pa...

aclaris-therapeutics-q2-eps-013-beats-014-estimate-sales-1777m-beat-1435m-estimate
Aclaris Therapeutics Q2 EPS $(0.13) Beats ...
08/07/2025 11:19:56

stock-market-today-us-future-edge-higher-ahead-of-fomc-decisionmeta-microsoft-earnings-in-focus
Stock Market Today: US Future Edge Higher ...
07/30/2025 09:53:40

U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indices were slightly higher.

aclaris-therapeutics-stock-spikes-in-afterhours-session-following-major-announcement
Aclaris Therapeutics Stock Spikes In After...
07/30/2025 07:07:33

Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 21:06:19

aclaris-therapeutics-reveals-top-line-results-from-open-label-phase-2a-trial-of-ati-2138--primary-endpoint-analysis-confirms-favorable-tolerability-profile-of-ati-2138-without-certain-risks-associated-with-other-agents-in-the-class-efficacy-results-show-comparable-outcomes-to-approved-therapies-with-potential-for-improved-tolerability-supporting-exploration-of-higher-doses-in-future-clinical-trials
Aclaris Therapeutics Reveals Top-Line Resu...
07/29/2025 20:04:25

WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical comp...

piper-sandler-assumes-aclaris-therapeutics-at-overweight-announces-price-target-of-6
Piper Sandler Assumes Aclaris Therapeutics...
07/10/2025 13:16:01

Piper Sandler analyst Biren Amin assumes Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight rating and announces Price Tar...

aclaris-therapeutics-added-to-russell-3000-and-russell-2000-indexes
Aclaris Therapeutics Added To Russell 3000...
06/30/2025 13:32:58

hc-wainwright--co-reiterates-buy-on-aclaris-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Acla...
06/25/2025 10:38:27

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $1...

aclaris-therapeutics-initiates-phase-1a1b-program-for-ati-052-the-companys-investigational-bispecific-anti-tslpil-4r-antibody-the-program-will-consist-of-a-phase-1a-single-and-multiple-ascending-dose-portion-in-healthy-volunteers-followed-by-an-expected-phase-1b-proof-of-concept-portion
Aclaris Therapeutics Initiates Phase 1a/1b...
06/23/2025 11:02:53

aclaris-therapeutics-has-initiated-a-randomized-double-blind-placebo-controlled-phase-2-trial-of-bosakitug-ati-045-for-moderate-to-severe-atopic-dermatitis-top-line-results-expected-in-the-second-half-of-2026
Aclaris Therapeutics Has Initiated A Rando...
06/02/2025 11:02:40

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/28/2025 12:08:42

this-arista-networks-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Arista Networks Analyst Begins Covera...
05/28/2025 11:43:44

wedbush-initiates-coverage-on-aclaris-therapeutics-with-outperform-rating-announces-price-target-of-8
Wedbush Initiates Coverage On Aclaris Ther...
05/28/2025 11:30:34

Wedbush analyst Martin Fan initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform rating and announces ...

hc-wainwright--co-maintains-buy-on-aclaris-therapeutics-lowers-price-target-to-16
HC Wainwright & Co. Maintains Buy on Aclar...
05/14/2025 17:10:30

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the pr...

aclaris-therapeutics-q1-eps-012-inline-sales-146m-beat-128m-estimate
Aclaris Therapeutics Q1 EPS $(0.12), Inlin...
05/08/2025 10:55:10

aclaris-therapeutics-fda-clears-ind-application-for-phase-1a1b-clinical-trial-of-ati-052-bispecific-anti-tslpil-4r-monoclonal-antibody-co-expects-to-initiate-trial-in-q2
Aclaris Therapeutics: FDA Clears IND Appli...
04/22/2025 11:02:31

- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 -WAYNE, Pa, April 22, 2025 (GLOBE NE...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION